Broj 10.


1. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015-22.

2. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80(3):276-81.

3. Poletti M, De Rosa A, Bonuccelli U. Affective symptoms and cognitive functions in Parkinson’s disease. J Neurol Sci. 2012;317(1-2):97-102.

4. GPDS. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord. 2002;17(1):60-7.

5. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord. 2003;18(4):414-8.

6. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13(2):187-96.

7. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;16(3):178-83.

8. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol Psychiatry. 2003;54(3):363-75.

9. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, et al. Anxiety rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2015-25.

10. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183-9; quiz 313.

11. Burn DJ, Landau S, Hindle JV, Samuel M, Wilson KC, Hurt CS, et al. Parkinson’s disease motor subtypes and mood. Mov Disord. 2012;27(3):379-86.

12. Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(5):585-9.

13. Grill S, Weuve J, Weisskopf MG. Predicting Outcomes in Parkinson’s Disease: Comparison of Simple Motor Performance Measures and the Unified Parkinson’s Disease Rating Scale-III. J Parkinsons Dis. 2011;1(3):287-98.

14. Liu CY, Wang SJ, Fuh JL, Lin CH, Yang YY, Liu HC. The correlation of depression with functional activity in Parkinson’s disease. J Neurol. 1997;244(8):493-8.

15. Troster AI, Paolo AM, Lyons KE, Glatt SL, Hubble JP, Koller WC. The influence of depression on cognition in Parkinson’s disease: a pattern of impairment distinguishable from Alzheimer’s disease. Neurology. 1995;45(4):672-6.

16. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson’s disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999;14(10):866-74.

17. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov Disord. 2002;17(3):445-54.

18. Kostić V. Parkinsonova bolest i parkinsonizam: Medicinski fakultet Univerziteta u Beogradu; 1998.

19. Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD. Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med. 1988;18(1):49-55.

20. American Academy of Family Physicians., American Psychiatric Association. Work Group on DSM-IV-PC. Diagnostic and statistical manual of mental disorders, fourth edition : primary care version. 1st ed. Washington, DC: American Psychiatric Association; 1995. xv, 223 p. p.

21. Leentjens AF, Lousberg R, Verhey FR. Markers for depression in Parkinson’s disease. Acta Psychiatr Scand. 2002;106(3):196-201.

22. Dissanayaka NN, Sellbach A, Silburn PA, O’Sullivan JD, Marsh R, Mellick GD. Factors associated with depression in Parkinson’s disease. J Affect Disord. 2011;132(1-2):82-8.

23. Leentjens AF, Moonen AJ, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, et al. Modeling depression in Parkinson disease: Disease-specific and nonspecific risk factors. Neurology. 2013.

24. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197-211.

25. Murai T, Muller U, Werheid K, Sorger D, Reuter M, Becker T, et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13(2):222-8.

26. Liu P, Feng T, Wang YJ, Zhang X, Chen B. Clinical heterogeneity in patients with early-stage Parkinson’s disease: a cluster analysis. J Zhejiang Univ Sci B. 2011;12(9):694-703.

27. Srikanth V, Beare R, Blizzard L, Phan T, Stapleton J, Chen J, et al. Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. Stroke. 2009;40(1):175-80.

28. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol. 1990;3(1):3-9.

29. Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry. 1990;147(1):22-30.

30. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99-103.

31. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243-54.

32. Starkstein SE, Leentjens AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry. 2008;79(10):1088-92.

33. Bogart KR. Is apathy a valid and meaningful symptom or syndrome in Parkinson’s disease? A critical review. Health Psychol. 2011;30(4):386-400.

34. Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):636-42.

35. Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson disease. Neurology. 2006;67(1):33-8.

36. Ziropadja L, Stefanova E, Petrovic M, Stojkovic T, Kostic VS. Apathy and depression in Parkinson’s disease: the Belgrade PD study report. Parkinsonism Relat Disord. 2012;18(4):339-42.

37. Moretti R, Torre P, Antonello RM, Rosin MV, Esposito F, Furman MR, et al. Apathy: a complex symptom specific to the clinical pattern of presentation of Parkinson’s disease? Am J Alzheimers Dis Other Demen. 2012;27(3):196-201.

38. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993;50(8):873-80.

39. Kranick SM, Duda JE. Olfactory dysfunction in Parkinson’s disease. Neurosignals. 2008;16(1):35-40.

40. Robert G, Le Jeune F, Lozachmeur C, Drapier S, Dondaine T, Peron J, et al. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology. 2012;79(11):1155-60.

41. Kostic VS, Agosta F, Petrovic I, Galantucci S, Spica V, Jecmenica-Lukic M, et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease. Neurology. 2010;75(10):857-63.

42. Bower JH, Grossardt BR, Maraganore DM, Ahlskog JE, Colligan RC, Geda YE, et al. Anxious personality predicts an increased risk of Parkinson’s disease. Mov Disord. 2010;25(13):2105-13.

43. Lauterbach EC, Duvoisin RC. Anxiety disorders in familial parkinsonism. Am J Psychiatry. 1991;148(2):274.

44. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Gironell A, Garcia-Sanchez C, Martinez-Corral M. Motor changes during sertraline treatment in depressed patients with Parkinson’s disease*. Eur J Neurol. 2008;15(9):953-9.

45. Dissanayaka NN, Sellbach A, Matheson S, O’Sullivan JD, Silburn PA, Byrne GJ, et al. Anxiety disorders in Parkinson’s disease: prevalence and risk factors. Mov Disord. 2010;25(7):838-45.

46. Goetz CG. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson’s disease. Mov Disord. 2010;25 Suppl 1:S104-9.

47. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov Disord. 2011;26(3):484-92.

48. Routh LC, Black JL, Ahlskog JE. Parkinson’s disease complicated by anxiety. Mayo Clin Proc. 1987;62(8):733-5.

49. Siemers ER, Shekhar A, Quaid K, Dickson H. Anxiety and motor performance in Parkinson’s disease. Mov Disord. 1993;8(4):501-6.

50. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. „Panic attacks“ in Parkinson’s disease. A long-term complication of levodopa therapy. Acta Neurol Scand. 1993;87(1):14-8.

51. Lauterbach EC, Freeman A, Vogel RL. Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease. Cogn Behav Neurol. 2003;16(4):225-33.

52. Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(3):257-64.

53. Raudino F. Non motor off in Parkinson’s disease. Acta Neurol Scand. 2001;104(5):312-5.

54. Cheon SM, Park MJ, Kim WJ, Kim JW. Non-motor off symptoms in Parkinson’s disease. J Korean Med Sci. 2009;24(2):311-4.

55. Richard IH, Frank S, McDermott MP, Wang H, Justus AW, LaDonna KA, et al. The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol. 2004;17(4):201-7.

56. Brown RG, Landau S, Hindle JV, Playfer J, Samuel M, Wilson KC, et al. Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2011;82(7):803-9.

57. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol. 2003;70(2):83-244.

58. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry. 2000;157(3):457-9.

59. Tessitore A, Hariri AR, Fera F, Smith WG, Chase TN, Hyde TM, et al. Dopamine modulates the response of the human amygdala: a study in Parkinson’s disease. J Neurosci. 2002;22(20):9099-103.

60. Ellgring H, Seiler S, Nagel U, Perleth B, Gasser T, Oertel WH. Psychosocial problems of Parkinson patients: approaches to assessment and treatment. Adv Neurol. 1990;53:349-53.

61. Prediger RD, Matheus FC, Schwarzbold ML, Lima MM, Vital MA. Anxiety in Parkinson’s disease: a critical review of experimental and clinical studies. Neuropharmacology. 2012;62(1):115-24.

62. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm. 2003;110(10):1119-27.

63. Bharmal A, Lu C, Quickfall J, Crockford D, Suchowersky O. Outcomes of patients with Parkinson disease and pathological gambling. Can J Neurol Sci. 2010;37(4):473-7.

Pages: 1 2 3 4 5

O časopisu Neurovesti

„Neurovesti“ predstavljaju elektronsku publikaciju Društva mladih neurologa Srbije sa besplatnim pristupom preko web-adrese, i dinamikom objavljivanja na mesečnom nivou.


Kalendar dešavanja
<< Dec 2021. >>
29 30 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 1 2
NOVO – Škola epilepsija – “Lečenje epilepsije vođeno etiologijom”